Enable JavaScript to visit this website.

What is XELJANZ?

XELJANZ (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:

  • Adults with moderately to severely active ulcerative colitis

It is not known if XELJANZ is safe and effective in children or in people with Hepatitis B or C.

XELJANZ is not recommended for people with severe liver problems.

XELJANZ is a pill, not an injection or infusion.

XELJANZ is the first and only FDA-approved pill for adults with moderate to severe UC

Three ways XELJANZ may be able to help you:

  • Can reduce symptoms in as early as 2 weeks.* *Symptoms include rectal bleeding and stool frequency.
  • Can improve the appearance of the intestinal lining.
  • Provide lasting steroid-free remission.

Ask your doctor if XELJANZ is right for you.

Pfizer would like to thank all the patients and investigators who took part in the clinical trials that led to the approval of XELJANZ for moderate to severe ulcerative colitis (UC).

Are you 18 or older? Have you been diagnosed with moderate to severe ulcerative colitis and been prescribed XELJANZ? We want to hear from you! Your stories are important - particularly for adult patients who are considering treatment or those who have just started. If selected, your story may appear in XELJANZ.com and/or in other marketing materials. Certain criteria must be met for consideration. Email us at [email protected] or call 877-744-3356.